Bicocca Open Archive

Logo unimib boa
GORI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.075
AS - Asia 7.664
EU - Europa 5.905
SA - Sud America 1.244
AF - Africa 195
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 7
Totale 30.103
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.644
SG - Singapore 2.828
CN - Cina 1.533
HK - Hong Kong 1.198
RU - Federazione Russa 1.064
BR - Brasile 930
VN - Vietnam 889
IT - Italia 855
SE - Svezia 774
IE - Irlanda 732
DE - Germania 672
UA - Ucraina 456
GB - Regno Unito 317
CA - Canada 277
FR - Francia 270
IN - India 244
FI - Finlandia 205
AT - Austria 160
BD - Bangladesh 147
TR - Turchia 145
AR - Argentina 118
IQ - Iraq 103
ID - Indonesia 94
MX - Messico 83
DK - Danimarca 82
ZA - Sudafrica 69
SA - Arabia Saudita 58
JP - Giappone 56
PK - Pakistan 52
KR - Corea 49
NL - Olanda 49
RO - Romania 48
EC - Ecuador 43
ES - Italia 42
BE - Belgio 41
CO - Colombia 40
PL - Polonia 38
UZ - Uzbekistan 38
PH - Filippine 37
VE - Venezuela 32
CL - Cile 28
MA - Marocco 24
TN - Tunisia 20
JO - Giordania 19
PY - Paraguay 19
AE - Emirati Arabi Uniti 17
IR - Iran 16
NP - Nepal 16
CZ - Repubblica Ceca 15
ET - Etiopia 15
CH - Svizzera 14
EG - Egitto 14
IL - Israele 14
KE - Kenya 14
MY - Malesia 14
OM - Oman 14
PA - Panama 13
PE - Perù 13
CR - Costa Rica 12
AZ - Azerbaigian 11
LB - Libano 11
UY - Uruguay 11
JM - Giamaica 10
LT - Lituania 10
TH - Thailandia 10
BO - Bolivia 9
EU - Europa 9
HN - Honduras 9
KZ - Kazakistan 9
AL - Albania 8
BH - Bahrain 8
DO - Repubblica Dominicana 8
GR - Grecia 8
PT - Portogallo 8
BG - Bulgaria 7
AU - Australia 6
SN - Senegal 6
DZ - Algeria 5
MD - Moldavia 5
PS - Palestinian Territory 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
BZ - Belize 4
HR - Croazia 4
NG - Nigeria 4
AO - Angola 3
BB - Barbados 3
BY - Bielorussia 3
KG - Kirghizistan 3
KH - Cambogia 3
ML - Mali 3
SI - Slovenia 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BW - Botswana 2
CI - Costa d'Avorio 2
EE - Estonia 2
GT - Guatemala 2
KW - Kuwait 2
LU - Lussemburgo 2
Totale 30.056
Salva come PNG Salva come JPEG
Città #
Singapore 1.609
Ann Arbor 1.412
Woodbridge 1.344
Fairfield 1.231
Hong Kong 1.181
Ashburn 1.149
Houston 1.025
Chandler 745
Dublin 716
San Jose 636
Jacksonville 567
Wilmington 546
Seattle 477
Frankfurt am Main 436
Cambridge 435
New York 384
Dearborn 319
Princeton 280
Ho Chi Minh City 268
Milan 259
Chicago 244
The Dalles 221
Beijing 219
Los Angeles 215
Santa Clara 206
Hanoi 197
Dallas 183
Nanjing 151
Altamura 133
Lauterbourg 133
Lawrence 133
Shanghai 125
Moscow 122
Vienna 122
Lachine 110
São Paulo 98
Buffalo 97
Dong Ket 83
Hefei 83
Helsinki 76
San Diego 75
Council Bluffs 73
Ottawa 56
Boardman 54
Jakarta 54
Andover 51
Fremont 50
London 49
Munich 47
Nanchang 47
Tokyo 45
Galati 43
Seoul 42
Hebei 41
Brussels 40
Shenyang 40
Baghdad 39
Toronto 38
Nuremberg 35
Rio de Janeiro 35
Salt Lake City 34
Johannesburg 32
Guangzhou 31
Orem 31
Tashkent 31
Hangzhou 30
Montreal 30
Norwalk 29
Denver 28
Da Nang 25
Falls Church 25
Tianjin 24
Changsha 23
Columbus 23
Florence 23
Kent 23
Amsterdam 22
Warsaw 22
Haiphong 21
Jeddah 21
Phoenix 21
Pune 21
Riyadh 19
Chennai 18
Cuauhtémoc 18
New Delhi 18
Brasília 17
Edmonton 17
Zhengzhou 17
Amman 16
Belo Horizonte 16
Boston 16
Dhaka 16
Rome 16
Stockholm 16
Biên Hòa 15
Elk Grove Village 15
Jiaxing 15
Kunming 15
Santiago 15
Totale 19.789
Salva come PNG Salva come JPEG
Nome #
Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells 434
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 404
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 339
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 314
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 314
Primary Whipple disease of the Central Nervous System presenting with rhombencephalitis 313
The CCR5Δ32 allele is not a major predisposing factor for severe H1N1pdm09 infection 312
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 307
HIV testing: A must for patients with inflammatory bowel disease 304
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 304
Comment on "Management of infections in cirrhotic patients: Report of a consensus conference" S Fagiuoli et al. [Dig Liver Dis 2014;46:204-212] 303
Brachial and central blood pressure in HIV-infected subjects 297
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 295
Strategies to limit immune-activation in HIV patients 295
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 289
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 286
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 280
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 278
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 276
Untargeted Mass Spectrometry Approach to Study SARS-CoV-2 Proteins in Human Plasma and Saliva Proteome 273
Combination versus sequential monotherapy in chronic HBV infection: A mathematical approach 271
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 269
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 265
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response 263
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 261
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 259
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 258
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study 256
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 254
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 251
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 249
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 247
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 246
Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: a pilot study 241
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 240
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 240
Focal bone lesions in hiv-positive patient treated with tenofovir 238
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 237
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 236
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 235
Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function 233
Unmasking tuberculosis in the era of antiretroviral treatment 231
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 231
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 231
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 229
Untargeted mass spectrometry approach to study SARS-CoV-2 proteins and characterize human plasma and saliva proteome in COVID-19 patients. 227
Arterial structure and function in AIDS patients: the impact of renal damage. 226
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 225
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 225
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 222
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 222
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 222
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 221
Neurocognitive impairment in HIV infected naïve patients: the role of genetic polymorphisms, viral changes and intrathecal immune activation 220
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 219
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 216
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study 216
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 214
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 213
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 213
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 212
Effects of antiretroviral therapy on endothelial function in HIV patients. 212
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 211
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial 209
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 209
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 204
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 204
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 204
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 202
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 201
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: A multilevel analysis 196
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 196
Structural and functional alterations of large arteries in HIV patients and their relationships with metabolic syndrome. 195
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 195
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 194
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 193
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 192
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 191
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 191
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 190
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 190
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy 190
Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure 190
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study 187
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 187
Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis 187
Antimicrobial therapy duration: A major matter in the management of severe infections 186
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 186
Inflammatory cytokines drive CD4+ t-cell cycling and impaired responsiveness to interleukin 7: Implications for immune failure in HIV disease 185
Impact of HAART with protease inhibitors treatment on carotid wall structure in HIV patients. 185
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 182
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 182
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 181
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 180
Plasma proteomic signatures related to COVID-19 disease severity by an untargeted nLC-ESI-MS/MS approach 179
Beyond the gut bacterial microbiota: The gut virome 179
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 178
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: A combined approach by QuantiFERON®-TB Gold and tuberculin skin tests 178
Re: The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options 177
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 177
Totale 23.356
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.503
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.503
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021477 0 0 0 0 0 0 0 0 0 212 89 176
2021/20221.509 40 103 212 146 73 135 61 124 72 118 116 309
2022/20232.909 369 803 233 291 188 471 31 167 210 28 72 46
2023/20242.086 43 72 97 81 283 552 427 80 145 49 35 222
2024/20254.704 285 525 358 211 390 156 241 170 571 748 366 683
2025/20269.239 1.129 635 815 1.005 1.237 612 1.463 522 929 892 0 0
Totale 31.049